ID Source | ID |
---|---|
PubMed CID | 853584 |
CHEMBL ID | 1718794 |
SCHEMBL ID | 544757 |
SCHEMBL ID | 16700823 |
MeSH ID | M0165793 |
Synonym |
---|
BIDD:GT0746 |
6-amino-3h-1,3-benzothiazole-2-thione |
AKOS002358657 |
2-benzothiazolethiol, 6-amino- |
6-amino-2-mercaptobenzothiazole , |
7442-07-1 |
usaf xr-30 |
2(3h)-benzothiazolethione, 6-amino- |
6-amino-2-benzothiazolethiol |
benzothiazole, 2-mercapto-6-amino- |
mls002638030 , |
benzothiazole, 6-amino-2-mercapto- |
nsc7916 |
nsc-7916 |
wln: t56 bn dsj csh gz |
nsc45347 |
nsc-45347 |
einecs 231-184-2 |
nsc 45347 |
nsc 7916 |
6-aminobenzothiazole-2-thiol |
OPREA1_252897 |
6-amino-2-mercaptobenzothiazole, 97% |
inchi=1/c7h6n2s2/c8-4-1-2-5-6(3-4)11-7(10)9-5/h1-3h,8h2,(h,9,10 |
A0682 |
smr000057954 |
AKOS000266332 |
6-amino-1,3-benzothiazole-2-thiol |
STK858658 |
HMS3078F19 |
GEO-00151 |
F3284-7445 |
6-aminobenzo[d]thiazole-2(3h)-thione |
AB02354 |
FT-0620909 |
6-amino-2-benzothiazole-thiol |
6-aminobenzothiazol-2-thiol |
6-aminobenzthiazol-2-thiol |
6-amino-benzothiazol-2-thiol |
SCHEMBL544757 |
DTXSID0064703 |
W-200061 |
6-aminobenzo[d]thiazole-2-thiol |
CHEMBL1718794 |
6-amino-1,3-benzothiazole-2-thiol # |
SCHEMBL16700823 |
mfcd00059164 |
AS-60585 |
6-amino-3h-benzothiazole-2-thione |
6-amino-2-mercapto-benzothiazole |
mfcd00227499 |
CS-0147957 |
A922931 |
EN300-98418 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 3.5481 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
TDP1 protein | Homo sapiens (human) | Potency | 16.3601 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 11.2202 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 14.1254 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 44.6684 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
67.9K protein | Vaccinia virus | Potency | 7.9433 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 28.1838 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 2.9935 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 47.7548 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 25.1189 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 44.6684 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
Alpha-synuclein | Homo sapiens (human) | Potency | 8.9125 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 30.4300 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1763211 | Inhibition of human chymotrypsin-like beta 5i subunit of iCP assessed as residual activity using suc-LLVY-AMC as flurogenic substrate at 100 uM for 90 mins by fluorescence-based assay | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Discovery of selective fragment-sized immunoproteasome inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |